Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Neurological lesion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurologic syndromes: localizing a lesion (Proceedings) When a veterinarian is presented with a patient with symptoms of difficulty walking, altered mentation, weakness, collapse or other movement disorders several potential causes must be considered.
Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions
ActiveUS20160278716A1Ease of evaluationConstant speedIntracranial pressure measurementSensorsDiseaseEtiology
The invention provides methods and kits for detecting, screening, quantifying or localizing the etiology for reduced or impaired cranial nerve function or conduction; localizing a central nervous system lesion; detecting, diagnosing or screening for increased intracranial pressure, pressure or disruption of central nervous system physiology as seen with concussion; or detecting, diagnosing, monitoring progression of or screening for a disease or condition featuring increased intracranial pressure or concussion by tracking eye movement of the subject.
Owner:NEW YORK UNIV +1
Device and method for treating central nervous system pathology
ActiveUS8267960B2Increase probabilityRisk minimizationMedical devicesIntravenous devicesNervous systemMedicine
The present invention relates generally to a device and method for treating tissues of the central nervous system and more particularly, but not exclusively, to a device and method for treating the brain tissue.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Method for preventing and treating peripheral neuropathy by administering selegiline
InactiveUS6239181B1Shorten the progressPreventing and reducing and eliminating peripheral neuropathyOrganic active ingredientsHeavy metal active ingredientsWhole bodyPeripheral neuron
The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.
Owner:SOMERSET PHARMA
Neuroprotective synergy of erythropoietin and insulin-like growth factors
InactiveUS20050197284A9Prevention and reduction of severityBiocideSenses disorderInsulin-like growth factorNervous system
The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.
Owner:BURNHAM INST FOR MEDICAL RES +1
Medicine for treating peripheral nervous disease of diabets mellitus and prepn. method
ActiveCN1833703ASignificant effectNervous disorderAnthropod material medical ingredientsDiseasePeripheral nerve
A Chinese medicine for treating the diabetic peripheral neuropathy is prepared from 13 Chinese-medicinal materials including astragalus root, rehmannia root, Chuan-xiong rhizome, Chinese angelica root, etc. Its preparing process is also disclosed.
Owner:SHIJIAZHUANG YILING PHARMA
Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy
The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.
Owner:STEMEDICA CELL TECH
Therapy device for edema and neuropathy
Disclosed is a therapy device for edema and neuropathy. Colored light within a visible light wavelength range, which is known to be useful for treating edema and neuropathy, is irradiated to a treatment area such as acupuncture points on a foot or a hand, or the surface of the skin, thereby relaxing the smooth muscle tissue of tissue cells with edema or neuropathy, facilitating peripheral vascular circulation and lymphatic circulation, and inducing the secretion of a material for treating edema and neuropathy.
Owner:COLOR SEVEN
Application of dioscin in preventing and treating diabetic complications
InactiveCN102048746AAlleviate and treat chronic complications of diabetesOrganic active ingredientsSenses disorderDiseaseDiabetes retinopathy
The invention discloses that dioscin has certain inhibition activity to rat lens AR, has certain delaying function to both galactose cataract and diabetic cataract, and can obviously reduce content of albumin in diabetic rat urine. So that the dioscin can prevent, delay and / or treat diabetic complications, particularly diseases, such as sugar cataract, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Mineral-protein preparations (mpp) and neuropathies in diabetes
InactiveUS20040175436A1Process can be stoppedReduce depositionBiocideNon-fibrous pulp additionAcute hyperglycaemiaInsulin dependent
The increased level of glucose in blood is the result of the destruction of beta cells of the Islets of Langerhans by autoimmune process in insulin-dependent form of diabetes or a relative lack of insulin in insulin-dependent form of diabetes. Constantly present hyperglycemia in daibetes and a relative lack of insulin aid the development of the neuropathy as a late complication of diabetes. For that purpose, a technical problem was set before the inventor with the request of the reduction of glucose in blood, and stopping of the process of the development of the neuropathy as the consequence of the "long" duration of diabetes. Such a mineral-protein preparation was prepared by which glycemia was successfully regulated, but the process was also stopped by depositing of Ca<+> in nerve cells. Those early changes caused by diabetes were successfully stopped, so that the appearance of the neuropathy, as a late complication in diabetes, was postponed. The mineral-protein preparation showed a hypoglycemia effect and stopped the development and progressing of the diabetic neuropathy.
Owner:BASIC HOLDINGS CO LTD +2
Neural stem cell preparation used for cerebral infarction treatment and bimodally traceable by magnetic resonance and fluorescence imaging
InactiveCN108774633AIncrease the number ofEnhance anti-apoptosisPeptide/protein ingredientsBlood/immune system cellsNervous systemTreatment effect
The invention constructs a FerritinH-T2A-Bcl2-EGFP-containing over-expressed lentivirus vector by utilizing a fusion gene with a nucleotide sequence as shown in SEQ ID NO: 3. The FerritinH-T2A-Bcl2-EGFP-containing overexpressed lentivirus vector can safely and efficiently perform three-gene combined modification on NSCs. Through overexpression of Bcl2 by modified stem cells, the anti-apoptosis andsurvival abilities of transplanted NSCs are enhanced; the number of effective survival stem cells is increased; and the treatment effect of cerebral infarction is improved. Through imaging of FerritinH and EGFP reporter genes, bimodal tracing of magnetic resonance and fluorescence imaging is performed on NSCs at a living level; and real-time, dynamic, non-invasive and systematic monitoring of transplanted NSCs is realized. Thus, an experimental basis is provided for promoting clinical transformation of stem cell treatment; a novel means is provided for further expounding of the mechanism of neural stem cell action; and important scientific significance and clinical application prospects in stem-cell substitutive treatment or transgenosis treatment of neurological lesions are achieved.
Owner:SUN YAT SEN UNIV
Use of treprostinil to treat neuropathic diabetic foot ulcers
The present invention describes novel methods for using 9-deoxy-2', 9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of foot ulcers in subjects with diabetic neurophathy. The invention also relates to kits for treatment and / or prevention of foot ulcers, comprising an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Owner:UNITED THERAPEUTICS CORP
Methods and kits for assessing neurological function and localizing neurological lesions
ActiveUS20190192063A1Integrity is damagedEase of evaluationIntracranial pressure measurementSensorsEtiologyDisease
The invention provides methods and kits for detecting, screening, quantifying or localizing the etiology for reduced or impaired cranial nerve function or conduction; localizing a central nervous system lesion; detecting, diagnosing or screening for increased intracranial pressure, pressure or disruption of central nervous system physiology as seen with concussion; or detecting, diagnosing, monitoring progression of or screening for a disease or condition featuring increased intracranial pressure or concussion by tracking eye movement of the subject. The invention also provides methods and kits useful for detecting, screening for or quantitating disconjugate gaze or strabismus, useful for diagnosing a disease characterized by disconjugate gaze or strabismus in a subject, useful for detecting, monitoring progression of or screening for a disease or condition characterized by disconjugate gaze or strabismus in a subject or useful for quantitating the extent of disconjugate gaze or strabismus. Further, the invention provides methods for assessing or quantifying structural and non-structural traumatic brain injury or diagnosing a disease characterized by or featuring structural and non-structural traumatic brain injury.
Owner:NEW YORK UNIV
Methods and kits for assessing neurological and ophthalmic function and localizing neurological lesions
ActiveUS20190046124A1Ease of evaluationConstant speedIntracranial pressure measurementSensorsDiseaseEtiology
Owner:NEW YORK UNIV +1
Stem cell therapy for the treatment of diabetic retinopathy and diabetic optic neuropathy
The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.
Owner:STEMEDICA CELL TECH
Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
Methods, apparatus, compositions and kits for inhibiting a disorder in a human patient, including non-cerebral neurovascular disorder or muscular headache pain, or loss of motor or sensory function, sympathetic tone or range or fluidity of motion that affect a nerve pathway at more than one locus associated with the disorder to inhibit the disorder. Alternatively or in addition, neuropathy associated with a disorder is treatable by palpating to determine a Keystone nerve essential to the neuropathy, applying pressure to determine a point of maximum discomfort or trigger of increased symptoms to identify a Levin Sign as a locus of initial intervention, and intervening to treat the neuropathy at the location of the Levin Sign by administering a pharmaceutically active agent, internal implanted or external neuro stimulation affecting the nerve pathway to inhibit the neuropathy.
Owner:BHL PATENT HLDG
Mineral-protein preparations (MPP) and neuropathies in diabetes
The increased level of glucose in blood is the result of the destruction of β cells of the Islets of Langerhans by autoimmune process in insulin-dependent form of diabetes or a relative lack of insulin in insulin-dependent form of diabetes. Constantly present hyperglycemia in diabetes and a relative lack of insulin aid the development of the neuropathy as a late complication of diabetes. For that purpose, a technical problem was set before the inventor with the request of the reduction of glucose in blood, and stopping of the process of the development of the neuropathy as the consequence of the “long” duration of diabetes. Such a mineral-protein preparation was prepared by which glycemia was successfully regulated, but the process was also stopped by depositing of Ca+ in nerve cells. Those early changes caused by diabetes were successfully stopped, so that the appearance of the neuropathy, as a late complication in diabetes, was postponed. The mineral-protein preparation showed a hypoglycemia effect and stopped the development and progressing of the diabetic neuropathy.
Owner:BASIC HOLDINGS CO LTD +2
Targeting NAD+ to Treat Chemotherapy and Radiotherapy Induced Cognitive Impairment, Neuropathies and Inactivity
ActiveUS20180125871A1Stimulate physical activityImprove cognitive abilityNervous disorderPeptide/protein ingredientsNeuropathy HIVRadiation therapy
Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and / or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject.
Owner:NEWSOUTH INNOVATIONS PTY LTD
Use of (S)-Roscovitine for Prevention and/or Treatment of Neurological Diseases
ActiveUS20100008927A1Prevent and reduce cerebral ischemiaReduce riskBiocideNervous disorderDiseasePediatrics
The present invention relates to the use of 6-(benzyl-amino)-2(S)-[[1-(hydroxymethyl) propyl]amino]-9-isopropylpurine) or at least one of its pharmaceutical acceptable salts for manufacturing a medication intended for the prevention and / or treatment of neurological diseases, in particular associated with neurological lesions.
Owner:CENT NAT DE LA RECHERCHE SCI
Chinese medicine Tangzhi'an for treating peripheral nerve lesion of diabetes
InactiveCN1124140CEasy to makeEasy to takeNervous disorderAnthropod material medical ingredientsCentipedeDiabetes mellitus
The Chinese medicine consists of roasted leech, cassia twig, Herba Asari, honey, centipede and other five Chinese medicinal materials. The medicine of the present invention can dredge the meridian passage, disperse blood clots, warming kidney, invigorating Yang, activate vital energy, stop pain, promote the secretion of saliva, moisten skin and promote blood circulation; and has total effective rate on diabetes of 91 % and no adverse reaction.
Owner:王兆凯
Medicine for treating peripheral nervous disease of diabets mellitus and prepn. method
ActiveCN100364590CSignificant effectNervous disorderAnthropod material medical ingredientsDiseasePeripheral nerve
A Chinese medicine for treating the diabetic peripheral neuropathy is prepared from 13 Chinese-medicinal materials including astragalus root, rehmannia root, Chuan-xiong rhizome, Chinese angelica root, etc. Its preparing process is also disclosed.
Owner:SHIJIAZHUANG YILING PHARMA
Neuropathy remedies
InactiveUS6884819B1Minimal adverse side effectHigh learning and memory disorder improvement actionBiocideNervous disorderDiseaseActive ingredient
The present invention provides a neurodegenerative disease therapeutic agent containing as its active ingredient a (15R)-isocarbacycline derivative indicated by the following formula [I] or a 15-deoxy-isocarbacycline derivative indicated by the following formula [III]: (wherein, R1 represents a C1-C6 alkylene group, and R2 represents a hydrogen atom, a C1-C7, alkyl group or protective group); or, (wherein, R1 and R2 are the same as those defined in formula [I]).
Owner:TEIJIN LTD +1
Administration of (S)-roscovitine for protection against and/or treatment of neurological diseases
Owner:CENT NAT DE LA RECHERCHE SCI
Use of dimiracetam in the treatment of chronic pain
ActiveUS20100129469A1Good effectHeavy metal active ingredientsBiocideHigh activityPathology diagnosis
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
Owner:NEUROTUNE AG
Method and device to investigate or treat painful neuropathy
InactiveUS20190008440A1Skin safeSharp contrastDiagnostics using spectroscopyOptical sensorsFiberPricking pain
A process and laser system for in vitro and in vivo pain research, pain clinical testing and pain management. In preferred embodiments of the present invention a diode laser operating at a 980 nm wavelength is used to produce warmth, tickling, itching, touch, burning, hot pain or pin-prick pain. The device and methods can be used for stimulation of a single nerve fiber, groups of nerve fibers, nerve fibers of single type only as well as more the one type of nerve fibers simultaneously. The device and the methods can be applied in a wide variety of situations involving the study and treatment of pain. Preferred embodiments of the present invention provide laser systems and techniques that permit mapping and selective activation of silent, C-mechano-insensitive fibers or A-delta or C-polymodal fibers, de-functionalization (depleting) of these fibers for the purpose of the treatment of peripheral neuropathy and monitoring of CGRP and substance P associated with stimulation of silent, C-mechano-insensitive fibers.
Owner:NEMENOV MIKHAIL
Physiotherapy equipment for treating peripheral nerve pathological changes of diabetes
InactiveCN101428165BFully excitedGood dynamic environmentArtificial respirationHuman bodyTransformer
A physiotherapy table for treating peripheral neuropathy due to diabetes belongs to the technical field of medical instruments, and comprises a power supply 1, an intelligent controller 2, a keystroke interface 3, a digital displayer 4, a polarity control circuit 5, an impulse control circuit 6, a self-checking circuit 7, a first booster transformer 8, an output electrode 9 and a housing 10. The physiotherapy table has the following advantages: using the mutual inductance between two coils to produce two opposite induced current; and using a double-surface electrode to form a loop in local parts, which can produce low-frequency sine wave to simulate the frequency and strength of stimulation of muscular bioelectricity, thereby improving blood and lymph circulation in local tissue, ensuringbioelectric currents of human body work normally, creating a microenvironment for peripheral nerve repair, serving the function of speeding up the growth of the neural axon and the proliferation of Schwann cells, and establishing a novel therapeutic mode in response to peripheral neuropathy due to diabetes.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Use of dimiracetam in the treatment of chronic pain
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
Owner:NEUROTUNE AG
Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.
Owner:ORCHID CHEM & PHARM LTD
Fumigation lotion for treating lower limb peripheral nerve pathological changes of diabetes patient
InactiveCN101433622AEasy to operateGood curative effectNervous disorderMetabolism disorderSide effectClinical care
The invention discloses a fumigant for treating peripheral neuropathy of lower limbs of a diabetic patient, which is characterized in that the fumigant is prepared from astragalus root, angelica, deer horn deglued, kuh-seng, paris polyphylla, dried rehmannia root, glycyrrhiza uralensis and phellodendron. The fumigant can effectively treat peripheral neuropathy of the lower limbs of the diabetic patient, and has the advantages of good curative effect, no toxic and side effect, low price and convenient clinical care.
Owner:康群 +2
Use of dimiracetam in the treatment of chronic pain
The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.
Owner:NEUROTUNE AG
Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
PendingUS20190015391A1Reduce and prevent occurrenceNervous disorderAmide active ingredientsChemotherapy inducedNeurological lesion
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 / CXCR2 receptor inhibitors, useful in the treatment and / or prevention of chemotherapy-induced neuropathy, preferably in the treatment and / or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.
Owner:DOMPE FARM SPA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com